Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00728936 · ClinicalTrials.gov registry record · Phase 1
Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients
A Phase 1 study, sponsored by Idera Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT00728936 is a Phase 1 study that has completed, run by Idera Pharmaceuticals. The registered enrollment target is 58 participants.
The verdict
NCT00728936, a Phase 1 study, has completed, sponsored by Idera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125.
Interventions
- DRUG Saline placebo
- DRUG IMO-2125
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2007-09 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00728936
The ClinicalTrials.gov registry entry for NCT00728936 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idera Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline placebo is the first listed.
NCT00728936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00728936 about?
NCT00728936 is a clinical study titled "Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients". First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125.
What is the current status of trial NCT00728936?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2007-09. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00728936?
The interventions under investigation include: Saline placebo (DRUG), IMO-2125 (DRUG).
Who is sponsoring clinical trial NCT00728936?
This trial is sponsored by Idera Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.